Drug · CHEMBL111
RIMONABANT
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. RIMONABANT. Drugs and targets, record CHEMBL111. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL111
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| CNR1 | Cannabinoid receptor 1 | Cannabinoid CB1 receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/1268 |
Source ChEMBL
Diseases17
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| obesity disorder | Approval | ATC and TTD | 18 | 14 | https://conductscience.org/library/drugs?q=MONDO_0011122 |
| type 2 diabetes mellitus | Phase 3 | ClinicalTrials.gov | 9 | 9 | https://conductscience.org/library/drugs?q=MONDO_0005148 |
| Overweight | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=HP_0025502 |
| inherited lipid metabolism disorder | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0002525 |
| nicotine dependence | Phase 3 | ClinicalTrials.gov | 3 | 2 | https://conductscience.org/library/drugs?q=MONDO_0008575 |
| Abdominal obesity | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=HP_0012743 |
| metabolic dysfunction-associated steatohepatitis | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0007027 |
| metabolic syndrome | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=EFO_0000195 |
| Moderate albuminuria | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=HP_0012594 |
| Prader-Willi syndrome | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0008300 |
1 to 10 of 17Source Open Targets
See all 17 diseasesTrials47
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00656487 | Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults | Phase 2 | 66 | 2017-05-15 | rimonabant | Its name | ClinicalTrials.gov |
| NCT00547118 | The Effects of Rimonabant, on Weight and Metabolic Risk Factors | Phase 2 | 17 | 2015-02-27 | rimonabant | Its name | ClinicalTrials.gov |
| NCT00263042 | Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes | Phase 3 | 18,695 | rimonabant | Its name | ClinicalTrials.gov | |
| NCT00459173 | Efficacy and Safety of Rimonabant as an Aid to Maintenance of Smoking Cessation | Phase 3 | 4,850 | rimonabant | Its name | ClinicalTrials.gov | |
| NCT00029861 | Obese Patients With or Without Comorbidities (RIO-North America) | Phase 3 | 3,045 | rimonabant | Its name | ClinicalTrials.gov | |
| NCT00734123 | Early Detection of Atherosclerosis: a Randomized Trial in the Primary Prevention of Cardiovascular Diseases. | Phase 4 | 2,948 | rimonabant | Its name | ClinicalTrials.gov | |
| NCT00405808 | Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose | Phase 3 | 2,666 | rimonabant | Its name | ClinicalTrials.gov | |
| NCT00325650 | Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes | Phase 3 | 2,420 | rimonabant | Its name | ClinicalTrials.gov | |
| NCT00386061 | Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe) | Phase 3 | 1,507 | rimonabant | Its name | ClinicalTrials.gov | |
| NCT00029848 | Obese Patients With Type 2 Diabetes | Phase 3 | 1,045 | rimonabant | Its name | ClinicalTrials.gov |
1 to 10 of 47
See all 47 trialsComparisons in its trials1
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| Rimonabant vs Placebo: serious adverse events | 0 of 8 | 0 of 9 | 17 | NCT00547118 |
Source Trial comparisons
Papers from its trials23
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials3
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Iowa Gambling Lite | 1 | 1 | ConductCognition |
| 1-Back Task | 1 | 1 | ConductCognition |
| 2-Back Task | 1 | 1 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL111
GET https://conductscience.org/api/drugs/v1/CHEMBL111/trials?page=2